Does Blue Cross Blue Shield Cover Saxenda?
Key numbers
- 3 mgStandard daily Saxenda (liraglutide) dose, injected under the skin once a daySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 0.6 mgStarting daily Saxenda dose, taken for the first week before weekly increasesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 16 weeksPoint after starting when adults' weight change is checked under the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 4%Minimum weight loss by adults at 16 weeks; less than this and the label says to stop SaxendaSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Liraglutide
At a glance
- Drug / Saxenda (liraglutide) 3 mg once-daily injection [1]
- Approved use / Weight management with diet and activity [1]
- Who it is for / Adults with obesity, or overweight plus a weight-related condition; ages 12+ above 60 kg with obesity [1]
- Generic option / FDA-approved generic liraglutide labels referencing Saxenda exist [2]
- Combination limit / Label says not recommended with another liraglutide product or any other GLP-1 receptor agonist [1]
What the Saxenda label covers
Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once daily under the skin of the abdomen, thigh, or upper arm, at any time of day and without regard to meals [1]. The labeled use is weight management alongside a reduced-calorie diet and more physical activity in the groups described above [1]. Plans that cover it may tie coverage to these labeled uses, but that is a plan decision.
Questions worth asking
The 16-week checkpoint in the label
Dosing starts at 0.6 mg daily for one week, then rises weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg daily from week 5 [1]. For adults, the label says to evaluate weight change 16 weeks after starting and to discontinue Saxenda if less than 4% of baseline body weight has been lost [1].
Generic liraglutide and compounded products
FDA-approved generic liraglutide labels that reference Saxenda exist, for example from Teva, Biocon, and Cipla [2]. Compounded drugs are not FDA approved and are not reviewed by FDA for safety, effectiveness, or quality before they are marketed [3]. On 2026-04-30, FDA proposed excluding liraglutide, semaglutide, and tirzepatide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need. Comments were due by 2026-06-29, and a final decision was not found [4].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does Blue Cross Blue Shield cover Saxenda?
What does the label say about the 16-week weight check?
What does the label say about combining Saxenda with other GLP-1 drugs?
References
Show all 4 referencesHide references
- U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
- U.S. Food and Drug Administration.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA.
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA.